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Neural stem cells and regeneration of injured spinal cord. Re-
cent progress in the stem cell biology has led much insight into
new therapeutic interventions aiming for the regeneration of
the damaged central nervous system. The major strategies can
be classified into two subgroups: (1) activation of endogenous
neural stem cells, and (2) cell transplantation therapies. In ei-
ther of these strategies, it is crucial to understand the underlying
mechanisms of maintenance, activation, and differentiation of
neural stem cells and subsequent process, including the migra-
tion, survival, and functional maturation of differentiated cells.
In this paper, we would like to summarize our recent findings
on the therapeutic interventions of the injured spinal cord, es-
pecially focusing on the development of treatment for the acute
phase of spinal cord injury with anti-interleukin (IL)-6 receptor
blocking antibody.
For many years it was thought that once the adult mam-
malian central nervous system was injured, it never regen-
erated. However, a paradigm shift is taking place in the
light of the progress of the stem cell biology [1, 2]. Pre-
viously, our research group has demonstrated the pres-
ence of endogenous neural stem-like cells in the adult
human brain in collaboration with Pincus et al [3] and
Roy et al [4] in the United States. This has given rise to the
hope that regenerative capacity persists in the adult mam-
malian central nervous system, and, in fact, neurogenesis
has been shown to be induced when the central nervous
system is exposed to damage due to cerebral ischemia,
etc. As a result, activation of endogenous stem cells is now
regarded as another important central nervous system re-
generation pathway in addition to cell transplantation.
INJURED SPINAL CORD AND NEURAL
STEM CELLS
Nevertheless, despite the presence of endogenous neu-
ral stem cells in the adult mammalian spinal cord, neu-
rogenesis is not thought to occur there, not only under
intact conditions, but even when injured [5]. Moreover,
it is also suggested that when the spinal cord is damaged,
undifferentiated cells that are positive for the interme-
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diate filament nestin and derived from cells close to the
central canal in the vicinity of the lesioned site vigor-
ously proliferate, migrate around the lesioned site, and
differentiate into astroglia. In other words, although en-
dogenous neural stem cells are present in the spinal cord
and they do proliferate after a spinal cord injury, almost
all of them differentiate into astroglia, not into neurons
or oligodendroglia, which are myelin-forming cells. Fur-
thermore, since the astroglia form glial scars around cysts
as time passes after the injury, regeneration of neuronal
axons disrupted by the injury, extension of axons past
the injury site, and remyelination of demyelinated neural
axons seemed to be impossible.
Nevertheless, since neural stem/progenitor cells de-
rived from the adult mammalian spinal cord were shown
to cause neurogenesis when transplanted into the hip-
pocampus, which is a neurogenic site [6]. Thus, the phe-
nomenon of the adult mammalian spinal cord being
nonneurogenic appears to be attributable to the microen-
vironment in the spinal cord of adult mammals and not
to be a cell-autonomous phenomenon of spinal-cord–
derived neural stem/progenitor cells. A study of changes
in the microenvironment in the injured spinal cord after
spinal cord injury in rats revealed that expression of the
mRNAs of a variety of proinflammatory cytokines [tu-
mor necrosis factor-a (TNF-a), interleukin (IL)-1a, IL-
1b , and IL-6] increased 6 to 12 hours after the injury and
peaked by 4 days [7]. These proinflammatory cytokines
were already known to exhibit cytotoxicity, including in-
duction of apoptosis of neurons and oligodendrocytes;
however, we focused our attention on the induction of IL-
6 expression, because leukemia inhibitory factor (LIF)
and ciliary neurotrophic factor (CNTF), which belong to
the IL-6 cytokine superfamily, are known to induce neu-
ral stem/progenitor cells to differentiate into astroglia by
activating the gp130/Janus kinase (JAK)/signal transduc-
ers and activators of transcription (STAT) pathway [8].
Because of that, the IL-6 whose expression is induced in
the spinal cord in the acute phase of the injury was ex-
pected to act on endogenous neural stem cells and induce
them to differentiate into (reactive) astroglia. The reac-
tive astroglia induced in the injured spinal cord are known
to express chondroitin sulfate proteoglycans (CSPGs),
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which are axonal growth inhibitors, and to inhibit axonal
regeneration [9].
BLOCKADE OF IL-6 SIGNALING IN
EXPERIMENTAL SPINAL CORD INJURY
Based on the above mentioned grounds, it was ex-
pected that inhibiting signal transduction by the IL-6
induced in the spinal cord in the acute phase of the in-
jury would inhibit the production of reactive astroglia
and of axonal regeneration inhibitors, such as CSPGs,
and would be linked to induction of regeneration of the
central nervous system. Administration of chondroiti-
nase ABC, which breaks down these CSPGs, to rats with
spinal cord injury has, in fact, been reported to be effec-
tive in regenerating axons and restoring function after
injuries [9], and the aspects of IL-6 as a proinflamma-
tory cytokine cannot be overlooked either. The concept
of so-called “secondary injury,” a self-destructive tissue
injury mechanism associated with spinal cord injury in
which the blood-spinal cord barrier breaks down, inflam-
matory cells such as macrophages and lymphocytes infil-
trate the spinal cord, and the infiltration is followed by
secondary scar formation, cavitation, and demyelination
has long been advanced. High-dose synthetic adrenocor-
tical steroid therapy (methylprednisolone) in the acute
phase is currently performed as the sole method of pre-
venting this secondary spinal cord injury, but its safety
and efficacy have been questioned. Because IL-6 plays a
major role in the differentiation of a variety of cells, in-
cluding B lymphocytes, T lymphocytes, and monocytes, it
was hoped that inhibition of signal transduction by IL-6
would have an inhibitory effect on secondary spinal cord
injury, and it was against this background that we investi-
gated the efficacy of administration of anti-IL-6 receptor
antibody in an animal model of the acute phase spinal
cord injury.
To confirm the impact of the IL-6 signal on the differen-
tiation of endogenous neural stem cells in the spinal cord,
we first examined it in vitro [10]. Neural stem cells were
harvested from the spinal cord of 8-week-old adult mice,
cultured by the neurosphere method, and allowed to dif-
ferentiate for 3 days in an in vitro system. The results
showed hardly any extension of neuronal processes by
the cells in the control group, whereas prominent nerve
process elongation was observed in the group to which
IL-6 and soluble IL-6 receptor (sIL-6R) had been added,
and the proportion of cells overall that had differenti-
ated into glial fibrillary acidic protein (GFAP)–positive
astroglia was also higher. However, when the anti-IL-6R
blocking antibody MR16-1 [11] was added in the pres-
ence of the IL-6 signal and the cells were cultured in the
same manner, the effect of the IL-6 signal was abolished,
suggesting that it is also possible to inhibit differenti-
ation of endogenous neural stem cells into astroglia in
vivo by blocking the IL-6 signal with anti-IL-6R blocking
antibody.
Next, we investigated the effect of the IL-6 signal on
glia scar formation in vivo in an actual spinal cord in-
jury in mice [10]. First, a laminectomy was performed at
the T9 level, and a spinal cord injury model was created
in the form of a contusion injury model by allowing a
3 g weight with a 1.2 mm diameter tip to drop from a
height of 25 mm. Anti-IL-6R blocking antibody was then
injected intraperitoneally in one shot (a similar dose of
rat IgG was injected in the control group), and we (1)
investigated expression of molecules related to the IL-6
signal by the immunoblot method 12 hours after the in-
jury, (2) 2 weeks later, immunostained tissue sections for
various markers, investigated the degree of reactive as-
trogliosis and macrophage infiltration, and investigated
whether neurogenesis had been induced, and (3) investi-
gated whether there was any behavioral improvement by
6 weeks after the injury (Fig. 1).
Investigation of the IL-6 signal
To confirm that the IL-6 signal had been blocked in
the injured spinal cord, 12 hours after the injury we used
the immunoblot method to check for phosphorylation of
STAT3, which is a molecule downstream from the IL-6
signal, and since it was also found to be significantly re-
duced in the anti-IL-6R blocking antibody group, we were
able to confirm that the preparation that was intraperi-
toneally injected in one shot immediately after the injury
had acted in the injured spinal cord.
Histochemical examination
To quantitatively evaluate reactive astrogliosis, 5-
bromo-2′-deoxyrudine (BrdU) was intraperitoneally in-
jected daily for 2 weeks after the injury, and the reactive
gliosis was quantitatively evaluated in the form of BrdU/
GFAP double positive cells. The results showed that reac-
tive astrogliosis in the center and periphery of the lesion
had been inhibited in the anti-IL-6R blocking antibody
group. On the other hand, a recent series of studies has
demonstrated that differentiation of neuron or astroglia
from neural stem cells is regulated in a mutually exclusive
mechanism [8, 12]. More specifically, it is now understood
that a complex (CBP/p300-phosphorylated Smad com-
plex) in which a transplantation factor that acts down-
stream of the bone morphogenetic protein (BMP) signal
[i.e., active Smad (phosphorylated Smad)], and the trans-
plantation coactivator CBP/p300 are bound in neural
stem/progenitor cells, which are capable of differentiating
into both the neuronal lineage and the astroglia lineage,
and that when the CBP/p300-phosphorylated Smad com-
plex forms a functional complex with phosphorylated
STAT3, they differentiate into astroglia lineage cells,
whereas when it forms complexes with a proneural-type
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Fig. 1. Administration of anti-interleukin
(IL)-6 receptor antibody (MR16-1) into spinal
cord injured animals. Immediately after the
contusion spinal cord injury was induced at
the T9 level, mice were intraperitoneally in-
jected with a single dose of MR16-1 or with
the same volume and concentration of pu-
rified rat IgG (control group). To quantify
the IL-6–mediated signaling, at 12 hours after
the injury, the amount of phosphorylated sig-
nal transducers and activators of transcription
(STAT3) within the spinal cord tissue of the le-
sion epicenter was measured by immunoblot-
ting. At 2 weeks after the injury, animals in
both the MR16-1 group and the control group
were immunohistochemically characterized.
By the 6 weeks after the injury, three differ-
ent tests were used to assess recovery of motor
function after the injury [10].
bHLH factor, such as neurogenin1/2, they differentiate
into the neuronal lineage. Since we observed a decrease
in phosphorylated STAT3 in the anti-IL-6R blocking
antibody group, we hypothesized that “if neurogenin-
expressing cells are present in injured spinal cord, it is
also possible that CBP/p300-phosphorylated Smad com-
plex will have a chance to bind to neurogenin1/2 in the
anti-IL-6R blocking antibody group, and for neurogene-
sis to be induced.” We expect that under certain condi-
tions neurogenesis also occurs in the spinal cord of adult
mammals, and that it is not an “absolute nonneurogenic
site,” as had previously been thought. The experimental
demonstration of neurogenesis in the adult central ner-
vous system is regarded as a finding that indicates just how
important the microenvironment is. We are currently in-
vestigating this possibility.
In addition, to assess the inhibitory effect of anti-IL-6R
blocking antibody administration on the inflammatory
response, 2 weeks after the injury, we quantitated the de-
gree of inflammatory cell infiltration by immunostaining
spinal cord tissue sections for Mac1 (CD11b), a marker of
inflammatory cells, including macrophages [10]. The re-
sults showed that infiltration by Mac1-positive cells in the
anti-IL-6R blocking antibody group had been inhibited to
one third the level of infiltration in the control group. We
quantitatively determined the size of the connective tis-
sue scars, which are thought to occur as a result of inflam-
matory cell infiltration, and compared them between the
anti-IL-6R blocking antibody group and control group,
but the region was significantly smaller at the center of
the lesioned site in anti-IL-6R blocking antibody group.
Based on these results, it appeared that blocking the IL-6
signal had inhibited the inflammatory reaction and sec-
ondary injury, and that a greater amount of normal tissue
had spared from destructive injury.
Behavioral analysis
Since the model of spinal cord injury was a model
of spinal cord contusion injury at the T9 level, we ob-
served hind limb paralysis. We therefore assessed efficacy
in the anti-IL-6R blocking antibody group by three dif-
ferent evaluations of motor function: spontaneous hind
limb motor function (BBB score), vertical righting, and
the Rota-Rod treadmill test to assess recovery of fore
limb-hind limb function. The results showed significantly
more favorable recovery in the anti-IL-6R blocking an-
tibody group than in the control group, and it was espe-
cially noteworthy that the anti-IL-6R blocking antibody
that had been administered in one shot immediately after
the injury contributed to long-term motor improvement
(observations until 6 weeks after the injury, which is the
chronic phase in the mouse). This is important because
it means that appropriate management and treatment in
the acute phase can have a major impact on the long-
term outcome. The mechanism of the phenomenon of
improvement in the motor function of the hind limbs in
response to administration of the antibody is thought to
have been that, by inhibiting the formation of glial scars,
it may have inhibited expression of axonal growth in-
hibitors contained in them and promoted axonal regen-
eration as a result, and that a great deal of normal tissue
was spared by the mitigation of secondary injury.
IL-6 has been thought to have a protective action on
nerve cells in vitro. There have even been reports of the
size of brain ischemia being reduced by administration of
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IL-6 [13], and its action seems to have varied consider-
ably according to the pathology, degree of expression of
the IL-6 signal, and the timing. However, when the IL-6
signal was overexpressed after spinal cord injury, its ac-
tion as a proinflammatory cytokine greatly exceeded its
neuroprotective effect, and the result was an increase in
the extent of the injury and severe impairment of axonal
regeneration instead [14]. The possibility that IL-6 ex-
erts a neurotrophic action from the subacute phase to the
chronic phase after the injury cannot be ruled out. How-
ever, because of its short half-life of only several days,
the anti-IL-6R blocking antibody has been postulated
to block the acute-phase neurotoxic IL-6 signal alone,
without interfering with the subsequent neuroprotective
action. Thus, we believe that it displays a very logical
pharmacologic action. In other words, through multiple
mechanisms, including inhibition of astrogliosis by en-
dogenous neural stem cells, induction of neurogenesis,
and inhibition of mobilization of inflammatory cells to
the injured spinal cord, depending on the varied func-
tions that IL-6 possesses, anti-IL-6R blocking antibody
shows promise of providing a new type of regeneration
therapy in the acute phase of spinal cord injury. Human-
ized monoclonal antibody against human IL-6R (MRA)
(Atlizumab) possesses an excellent IL-6 signal-inhibiting
effect. Its safety and metabolic distribution and tolerance
are being investigated in detail, and clinical research in
the treatment of inflammatory diseases, such as rheuma-
toid arthritis, Crohn’s disease, Castleman’s disease, has
progressed [15–17]. It is currently regarded as capable
of becoming an acute-phase treatment for spinal cord
injury instead of high-dose steroids, whose efficacy has
been questioned, and we are setting up a system that will
enable early clinical studies.
THERAPEUTIC TIME WINDOW FOR STEM
CELL TRANSPLANTATION INTO INJURED
SPINAL CORD
The findings that proper regulation of IL-6 signaling
is beneficial for treatment of spinal cord injury are also
relevant to determine the therapeutic time window of
the neural stem/precursor cell transplantation into the in-
jured spinal cord [1, 2]. Previously, we showed that adult
spinal cords are not absolutely nonpermissive for neu-
rogenesis from the transplanted neural stem/precursor
cells, however, and that a narrow therapeutic time win-
dow can allow successful transplantation [18]. This brief
window of opportunity might arise because the microen-
vironment in the host spinal cord changes rapidly af-
ter the injury. As already mentioned, during the acute
phase, which immediately follows the injury, the levels
of many pro-inflammatory cytokines (such as IL-1, IL-6,
and TNF-a) that have neurotoxic or astrocyte-inducing
effects, increase and then decline sharply within 24 hours
[7], indicating that the microenvironment of the acute
phase is not suitable for survival and/or neuronal dif-
ferentiation of grafted cells [1, 2]. However, the mi-
croenvironments appear to change into a more favorable
situation for neuronal differentiation and survival after-
ward. In fact, the transplantation of in vitro expanded
neural stem/precursor cells results in mitogenic neuroge-
nesis when the transplantation into the injured adult rat
spinal cord is carried out 9 days after injury, but not when
the transplantation is done within a few days of the injury
[18]. The chronic phase of spinal cord injury is not likely
to be appropriate for therapeutic transplantation due to
the lack of inducing factor for neurogenesis [Okada H,
et al, submitted for publication] or due to formation of en-
larged cysts and the development of glial scarring, which
might inhibit axonal regeneration [1, 2].
Taken together, we can conclude that the microenvi-
ronments within the injured spinal cord are major deter-
minants for the fates of both endogenous neural stem cells
and exogenously transplanted neural stem/precursor
cells. These facts would give us deep insights for develop-
ment of new therapeutic interventions.
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